GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6

The primary objective of this phase 1 study was to evaluate the safety and tolerability of the anti-glucose regulated protein 78 monoclonal immunoglobulin M antibody PAT-SM6 in subjects with relapsed or refractory multiple myeloma. Twelve heavily pretreated patients received four intravenous infusio...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Leo Rasche, Johannes Duell, Inês C. Castro, Valentina Dubljevic, Manik Chatterjee, Stefan Knop, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Max S. Topp, Stephanie Brändlein
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Ferrata Storti Foundation 2015-03-01
Saila:	Haematologica
Sarrera elektronikoa:	https://haematologica.org/article/view/7310
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!